Literature DB >> 33990617

STAT1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses.

Ori Scott1,2,3, Kyle Lindsay4, Steven Erwood4,5, Antonio Mollica4,6, Chaim M Roifman7,8, Ronald D Cohn4,9,5,10, Evgueni A Ivakine11,12.   

Abstract

Signal transducer and activator of transcription 1 (STAT1) gain-of-function (GOF) is an autosomal dominant immune disorder marked by wide infectious predisposition, autoimmunity, vascular disease, and malignancy. Its molecular hallmark, elevated phospho-STAT1 (pSTAT1) following interferon (IFN) stimulation, is seen consistently in all patients and may not fully account for the broad phenotypic spectrum associated with this disorder. While over 100 mutations have been implicated in STAT1 GOF, genotype-phenotype correlation remains limited, and current overexpression models may be of limited use in gene expression studies. We generated heterozygous mutants in diploid HAP1 cells using CRISPR/Cas9 base-editing, targeting the endogenous STAT1 gene. Our models recapitulated the molecular phenotype of elevated pSTAT1, and were used to characterize the expression of five IFN-stimulated genes under a number of conditions. At baseline, transcriptional polarization was evident among mutants compared with wild type, and this was maintained following prolonged serum starvation. This suggests a possible role for unphosphorylated STAT1 in the pathogenesis of STAT1 GOF. Following stimulation with IFNα or IFNγ, differential patterns of gene expression emerged among mutants, including both gain and loss of transcriptional function. This work highlights the importance of modeling heterozygous conditions, and in particular transcription factor-related disorders, in a manner which accurately reflects patient genotype and molecular signature. Furthermore, we propose a complex and multifactorial transcriptional profile associated with various STAT1 mutations, adding to global efforts in establishing STAT1 GOF genotype-phenotype correlation and enhancing our understanding of disease pathogenesis.

Entities:  

Year:  2021        PMID: 33990617     DOI: 10.1038/s41525-021-00196-7

Source DB:  PubMed          Journal:  NPJ Genom Med        ISSN: 2056-7944            Impact factor:   8.617


  68 in total

Review 1.  JAK-STAT signaling: from interferons to cytokines.

Authors:  Christian Schindler; David E Levy; Thomas Decker
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

Review 2.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

3.  Rapid activation by interferon alpha of a latent DNA-binding protein present in the cytoplasm of untreated cells.

Authors:  T C Dale; A M Imam; I M Kerr; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Severe impairment of IFN-γ and IFN-α responses in cells of a patient with a novel STAT1 splicing mutation.

Authors:  Donatella Vairo; Laura Tassone; Giovanna Tabellini; Nicola Tamassia; Sara Gasperini; Flavia Bazzoni; Alessandro Plebani; Fulvio Porta; Luigi D Notarangelo; Silvia Parolini; Silvia Giliani; Raffaele Badolato
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

5.  Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro.

Authors:  D E Levy; D S Kessler; R Pine; J E Darnell
Journal:  Genes Dev       Date:  1989-09       Impact factor: 11.361

6.  Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency.

Authors:  Stéphanie Dupuis; Emmanuelle Jouanguy; Sami Al-Hajjar; Claire Fieschi; Ibrahim Zaid Al-Mohsen; Suliman Al-Jumaah; Kun Yang; Ariane Chapgier; Céline Eidenschenk; Pierre Eid; Abdulaziz Al Ghonaium; Haysam Tufenkeji; Husn Frayha; Suleiman Al-Gazlan; Hassan Al-Rayes; Robert D Schreiber; Ion Gresser; Jean-Laurent Casanova
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

7.  Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo.

Authors:  Ariane Chapgier; Robert F Wynn; Emmanuelle Jouanguy; Orchidée Filipe-Santos; Shenying Zhang; Jacqueline Feinberg; Kay Hawkins; Jean-Laurent Casanova; Peter D Arkwright
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

Review 8.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

9.  A partial form of recessive STAT1 deficiency in humans.

Authors:  Ariane Chapgier; Xiao-Fei Kong; Stéphanie Boisson-Dupuis; Emmanuelle Jouanguy; Diana Averbuch; Jacqueline Feinberg; Shen-Ying Zhang; Jacinta Bustamante; Guillaume Vogt; Julien Lejeune; Eleonore Mayola; Ludovic de Beaucoudrey; Laurent Abel; Dan Engelhard; Jean-Laurent Casanova
Journal:  J Clin Invest       Date:  2009-05-11       Impact factor: 14.808

Review 10.  A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses.

Authors:  Agata Michalska; Katarzyna Blaszczyk; Joanna Wesoly; Hans A R Bluyssen
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

View more
  2 in total

Review 1.  CRISPR/Cas therapeutic strategies for autosomal dominant disorders.

Authors:  Salvatore Marco Caruso; Peter Mj Quinn; Bruna Lopes da Costa; Stephen H Tsang
Journal:  J Clin Invest       Date:  2022-05-02       Impact factor: 19.456

2.  Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis.

Authors:  Marketa Bloomfield; Irena Zentsova; Tomas Milota; Anna Sediva; Zuzana Parackova
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.